Terms: = Uterine cancer AND PPP2R1A, PR65A, 5518, ENSG00000105568, MGC786, P30153
52 results:
1. TERT promoter mutations and gene amplification in endometrial cancer.
Praiss AM; Marra A; Zhou Q; Rios-Doria E; Momeni-Boroujeni A; Iasonos A; Selenica P; Brown DN; Aghajanian C; Abu-Rustum NR; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Dec; 179():16-23. PubMed ID: 37890416
[TBL] [Abstract] [Full Text] [Related]
2. ECPPF (E2F1, CCNA2, POLE, ppp2r1a, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
[TBL] [Abstract] [Full Text] [Related]
3. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract] [Full Text] [Related]
4. uterine lavage identifies cancer mutations and increased
Ghezelayagh TS; Kohrn BF; Fredrickson J; Manhardt E; Radke MR; Katz R; Gray HJ; Urban RR; Pennington KP; Liao JB; Doll KM; Simons EJ; Burzawa JK; Goff BA; Speiser P; Swisher EM; Norquist BM; Risques RA
Cancer Res Commun; 2022 Oct; 2(10):1282-1292. PubMed ID: 36311816
[TBL] [Abstract] [Full Text] [Related]
5. Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y; Gim JA
J Gynecol Oncol; 2022 May; 33(3):e29. PubMed ID: 35128859
[TBL] [Abstract] [Full Text] [Related]
6. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract] [Full Text] [Related]
7. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract] [Full Text] [Related]
9. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract] [Full Text] [Related]
10. Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis.
Yoshida H; Asami Y; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Shiraishi K; Kato T
Virchows Arch; 2022 Jul; 481(1):117-123. PubMed ID: 34791535
[TBL] [Abstract] [Full Text] [Related]
11. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
12. uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract] [Full Text] [Related]
13. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract] [Full Text] [Related]
14. Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma.
Ashley CW; Da Cruz Paula A; Ferrando L; Gularte-Mérida R; Sebastiao APM; Brown DN; Gazzo AM; Pareja F; Stylianou A; Abu-Rustum NR; Reis-Filho JS; Buehler D; Weisman P; Chiang S; Weigelt B
Histopathology; 2021 Aug; 79(2):176-186. PubMed ID: 33527450
[TBL] [Abstract] [Full Text] [Related]
15. Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.
Bosquet JG; Zhang Q; Cliby WA; Bakkum-Gamez JN; Cen L; Dowdy SC; Sherman ME; Weroha SJ; Clayton AC; Kipp BR; Halling KC; Couch FJ; Podratz KC
PLoS One; 2021; 16(1):e0245664. PubMed ID: 33503056
[TBL] [Abstract] [Full Text] [Related]
16. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
[TBL] [Abstract] [Full Text] [Related]
17. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract] [Full Text] [Related]
18. Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study.
Cuevas D; Velasco A; Vaquero M; Santacana M; Gatius S; Eritja N; Estaran E; Matias-Guiu X
Histopathology; 2020 Feb; 76(3):447-460. PubMed ID: 31550396
[TBL] [Abstract] [Full Text] [Related]
19. Precision Therapy for Aggressive Endometrial cancer by Reactivation of Protein Phosphatase 2A.
Haines K; Huang GS
Cancer Res; 2019 Aug; 79(16):4009-4010. PubMed ID: 31416848
[TBL] [Abstract] [Full Text] [Related]
20. The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Taylor SE; O'Connor CM; Wang Z; Shen G; Song H; Leonard D; Sangodkar J; LaVasseur C; Avril S; Waggoner S; Zanotti K; Armstrong AJ; Nagel C; Resnick K; Singh S; Jackson MW; Xu W; Haider S; DiFeo A; Narla G
Cancer Res; 2019 Aug; 79(16):4242-4257. PubMed ID: 31142515
[TBL] [Abstract] [Full Text] [Related]
[Next]
